Animal Testing And Non-Animal Alternative Testing Market Players Invest In Novel Technologies As Per The Business Research Company's Animal Testing And Non-Animal Alternative Testing Global Market Report 2022

Jan 26, 2022•over 3 years ago

Cheshire

Description

According to The Business Research Company’s research report on the animal testing and non-animal alternative testing market, non-animal testing technologies are increasingly being adopted in preclinical research studies because most of the drugs/molecules tested on animals fail in clinical studies. Some drugs are also rejected at the regulatory review due to lack of safety and efficacy, which in turn increases the need for new non-animal testing technologies for drug development.

Company Information

Company

Technologies

Location

Cheshire, Connecticut, United States

About

The company has developed an innovative treatment that addresses the cause of the disease rather than the symptoms. The company has developed a patented molecule (AmyTrap) with demonstrated success in animal-model proof of concept studies to remove amyloid-beta, which is the physiological cause behind the plaque buildup in the brain associated with Alzheimer's Disease. Alzheimer's hits everybody hard; not just the sufferer who struggles with unimaginable frustration trying to remember the simplest of things; everyone around them feels pain and anguish watching someone close to them suffer. Recombinant Technologies has developed a unique treatment to a devastating medical problem to alleviate the anguish and bring relief.Continue Reading Recombinant Technologies has received multiple peer-reviewed grants (which in itself is a stamp of approval) from the National Institutes of Health to develop this Amytrapper devices.